房颤合并二尖瓣或主动脉瓣疾病抗凝患者的结局
基于ARISTOTLE试验中14 793例房颤患者,按二尖瓣反流、主动脉瓣反流或主动脉瓣狭窄分组,比较卒中/系统性栓塞、出血等结局及阿哌沙班与华法林疗效。结果显示主动脉瓣狭窄患者卒中/系统性栓塞、死亡、大出血及颅内出血风险显著升高,而阿哌沙班相对华法林的疗效与安全性在各瓣膜病亚组中一致。
要点
- 房颤合并主动脉瓣狭窄患者卒中/系统性栓塞、死亡及出血风险显著高于无主动脉瓣狭窄者。
- 二尖瓣反流或主动脉瓣反流患者卒中/系统性栓塞及出血率与无相应瓣膜病者相似。
- 阿哌沙班较华法林降低卒中/系统性栓塞的优效性在各瓣膜病亚组中一致。
核心结论
- 在抗凝房颤患者中,主动脉瓣狭窄与更高的卒中/系统性栓塞、出血和死亡风险相关。
- 阿哌沙班相比华法林的疗效与安全性获益在伴或不伴二尖瓣反流、主动脉瓣反流或主动脉瓣狭窄的患者中一致。
研究设计与样本
- 基于ARISTOTLE试验的事后分析,纳入14 793例已知瓣膜性心脏病状态的房颤患者。
- 按中度或重度二尖瓣反流(n=3382)、主动脉瓣反流(n=842)、主动脉瓣狭窄(n=324)及无显著瓣膜性心脏病分组比较。
- 中度或重度二尖瓣狭窄患者被排除于该试验。
主要发现
- 主动脉瓣狭窄患者卒中/系统性栓塞发生率为3.47/100患者年,无主动脉瓣狭窄者为1.36/100患者年(adjHR 2.21,95%CI 1.35至3.63)。
- 主动脉瓣狭窄患者死亡发生率为8.30/100患者年,无主动脉瓣狭窄者为3.53/100患者年(adjHR 1.92,95%CI 1.41至2.61)。
- 主动脉瓣狭窄患者大出血发生率为5.31/100患者年,无主动脉瓣狭窄者为2.53/100患者年(adjHR 1.80,95%CI 1.19至2.75)。
- 主动脉瓣狭窄患者颅内出血发生率为1.29/100患者年,无主动脉瓣狭窄者为0.51/100患者年(adjHR 2.54,95%CI 1.08至5.96)。
- 二尖瓣反流或主动脉瓣反流患者卒中/系统性栓塞及出血率与无相应瓣膜病者相似。
关键数值与推荐
- 阿哌沙班 vs 华法林对卒中/系统性栓塞的疗效:伴二尖瓣反流HR 0.69(95%CI 0.46至1.04)vs 不伴HR 0.79(95%CI 0.63至1.00),交互P=0.52。
- 伴主动脉瓣反流HR 0.57(95%CI 0.27至1.20)vs 不伴HR 0.78(95%CI 0.63至0.96),交互P=0.52。
- 伴主动脉瓣狭窄HR 0.44(95%CI 0.17至1.13)vs 不伴HR 0.79(95%CI 0.64至0.97),交互P=0.19。
- 各主要和次要疗效及安全性结局均无证据显示阿哌沙班相对华法林的效果在任一瓣膜病亚组中存在差异。
临床怎么用
- 房颤合并主动脉瓣狭窄患者抗凝时应认识到其卒中/系统性栓塞、出血及死亡风险较高。
- 房颤合并二尖瓣反流、主动脉瓣反流或主动脉瓣狭窄时,阿哌沙班相对华法林的疗效与安全性获益与无相应瓣膜病者一致。
局限性
- 中度或重度二尖瓣狭窄患者被排除,结果不适用于该人群。
- 瓣膜性心脏病亚组样本量较小,尤其主动脉瓣狭窄仅324例。
- 为ARISTOTLE试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess stroke/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. METHODS: There were 14 793 patients with known VHD status, categorised as having moderate or severe mitral regurgitation (MR) (n=3382), aortic regurgitation (AR) (n=842) or aortic stenosis (AS) (n=324); patients with moderate or severe mitral stenosis were excluded from the trial. Baseline characteristics, efficacy and safety outcomes were compared between each type and no significant VHD. Treatment effect was assessed using an adjusted model. RESULTS: Patients with MR or AR had similar rates of stroke/systemic embolism and bleeding compared with patients without MR or AR, respectively. Patients with AS had significantly higher event rates (presented as rate per 100 patient-years of follow-up) of stroke/systemic embolism (3.47 vs 1.36; adjusted HR (adjHR) 2.21, 95% CI 1.35 to 3.63), death (8.30 vs 3.53; adjHR 1.92, 95% CI 1.41 to 2.61), major bleeding (5.31 vs 2.53; adjHR 1.80, 95% CI 1.19 to 2.75) and intracranial bleeding (1.29 vs 0.51; adjHR 2.54, 95% CI 1.08 to 5.96) than patients without AS. The superiority of apixaban over warfarin on stroke/systemic embolism was similar in patients with versus without MR (HR 0.69, 95% CI 0.46 to 1.04 vs HR 0.79, 95% CI 0.63 to 1.00; interaction P value 0.52), with versus without AR (HR 0.57, 95% CI 0.27 to 1.20 vs HR 0.78, 95% CI 0.63 to 0.96; interaction P value 0.52), and with versus without AS (HR 0.44, 95% CI 0.17 to 1.13 vs HR 0.79, 95% CI 0.64 to 0.97; interaction P value 0.19). For each of the primary and secondary efficacy and safety outcomes, there was no evidence of a different effect of apixaban over warfarin in patients with any VHD subcategory. CONCLUSIONS: In anticoagulated patients with AF, AS is associated with a higher risk of stroke/systemic embolism, bleeding and death. The efficacy and safety benefits of apixaban compared with warfarin were consistent, regardless of presence of MR, AR or AS. CLINICAL TRIAL REGISTRATION: ARISTOTLE clinical trial number NCT00412984.
引用
- Vinereanu D, Wang A, Mulder H, et al. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018. PMID: 29352007. doi:10.1136/heartjnl-2017-312272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。